small molecule

NORVIR

RITONAVIR

Loss of exclusivityloss of exclusivity
CompanyAbbVie Inc.See this company's full patent-cliff portfolio

Drug detail

Brand nameNORVIR
Active ingredientRITONAVIR
Strength80MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 1996
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NORVIR patent cliff — loss of exclusivity — | CliffBio